CytRx Corporation (CYTR) Advancing Aldoxorubicin (INNO-206) Development With Pharmacokinetic Study in Patients With Metastatic Solid Tumors
10/15/2012 10:10:38 AM
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, has initiated an open-label, single-center Phase 1b clinical trial to evaluate the pharmacokinetics of its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly known as INNO-206) in patients with metastatic solid tumors who have either relapsed or not responded to treatment with standard therapies. The data obtained from this study will identify the duration of exposure after infusion of aldoxorubicin as well as define the peak drug levels reached after treatment with two different doses of the drug.
comments powered by